Kalbe Genexine Biologics (KGBio) is an Indonesia-based life sciences company. Global private equity firm General Atlantic invested $55 million in the company's first round. The investment was made to acquire a minority stake in KGBio. The transaction was announced in a press statement. The article does not disclose product details, operating metrics, valuation, or use of proceeds.

Total raised

$55M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2021